The concern about Rytary (levodopa/carbidopa) and melanoma is a real one worth discussing with a neurologist or dermatologist. There has been a long-standing question about whether levodopa may be associated with an increased risk of melanoma (a type of skin cancer).
Here's what is generally understood:
- Levodopa is Show Full Answer
The concern about Rytary (levodopa/carbidopa) and melanoma is a real one worth discussing with a neurologist or dermatologist. There has been a long-standing question about whether levodopa may be associated with an increased risk of melanoma (a type of skin cancer).
Here's what is generally understood:
- Levodopa is converted in the body into dopamine, and it also plays a role in the production of melanin — the pigment in skin
- Because of this connection, there has been concern that levodopa could potentially stimulate melanoma growth
- It is not fully proven that levodopa *causes* melanoma, but people with Parkinson's do appear to have a higher rate of melanoma compared to the general population
- This may be a biological link between Parkinson's itself and melanoma, rather than solely a medication effect
Due to this potential link, it is generally recommended that:
1. Regular skin checks with a dermatologist are a good idea
2. Any new or changing moles or skin lesions should be reported promptly
3. A doctor should be consulted before stopping or changing any Parkinson's medication
It's important not to stop taking Rytary or any [[treatment:levodopa/carbidopa:55d534f51fcaa397470006dd]] medication without speaking to a doctor first, as stopping suddenly can cause serious complications.
AI-generated responses are not a substitute for medical advice. These services are not intended to
diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.
Understanding Dopamine and Parkinson’s Disease
July 7
Join
Your Privacy Choices
